Position
Marex Group plc in Propanc Biopharma, Inc.
Back to the book · All holders of PPCB
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$28.2K$0.54 → $0.11
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 65K | $35.1K | — | — | — | 0.0% |
| Q1 2026 | 67.7K | $7.18K | $0.11 | −$28.2K | $286 | 0.0% |